PCSK9i
Medical abbreviation · Drug Class
| Stands for | PCSK9 inhibitor |
|---|---|
| Categories | Medical |
PCSK9i stands for PCSK9 inhibitor, a drug class abbreviation.
Cholesterol-lowering drugs that block proprotein convertase subtilisin/kexin type 9, increasing LDL receptors on the liver. Evolocumab and alirocumab are monoclonal antibodies injected every two or four weeks; inclisiran is a small interfering RNA given twice yearly.
Example: LDL 112 on max statin and ezetimibe after MI; add PCSK9i evolocumab 140 mg q2wk.
Usage notes
Evolocumab and alirocumab, both approved in 2015, lower LDL cholesterol by about 60 percent, and the FOURIER and ODYSSEY OUTCOMES trials showed fewer cardiovascular events. The target was discovered through families with genetic mutations causing very high or very low cholesterol. High prices initially required prior authorization for most patients.
Related abbreviations
More drug class abbreviations
- OHA – Oral hypoglycemic agent
- OIT – Oral immunotherapy
- P-CAB – Potassium-competitive acid blocker
- P2Y12i – P2Y12 inhibitor
- PAMORA – Peripherally acting mu-opioid receptor antagonist
- PARPi – Poly(ADP-ribose) polymerase inhibitor
- PDE5i – Phosphodiesterase-5 inhibitor
- PGA – Prostaglandin analog
- PI – Protease inhibitor
- PPI – Proton pump inhibitor
- SABA – Short-acting beta2-agonist
- SAMA – Short-acting muscarinic antagonist
See all 113 drug class abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.